Study Identifies How Ovarian Cancer Protects Itself, Paves Way for Improved Immunotherapy Approach

Study finds ovarian cancer cells produce a molecule called Interleukin-4 (IL-4), which is associated with asthma and the skin condition eczema, also known as atopic dermatitis.

The study used a cutting-edge spatial genomics technology and preclinical animal models to study ovarian cancer.

The cancer cells used IL-4 to create a protective environment that kept away killer immune cells, making the tumors resistant to immunotherapy.

A drug, dupilumab, which blocks the activity, has been approved by the Food and Drug Administration .

The investigators stress that clinical trials are essential to determine whether targeting IL-4 can enhance patient outcomes.

Given that dupilumab is already FDA -approved for asthma and eczema, there is potential for swift clinical testing alongside immunotherapy to enhance survival in ovarian cancer patients.

Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time.

The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers.

The Mount Sinai Hospital is on the U.S. News & World Report “ Best Hospitals” Honor Roll for 2024-2025 .